Company profile

Celltrion Healthcare Canada Limited

Industry
Pharmaceutical Manufacturing
Employees
54
Headquarters
Toronto, Ontario
LinkedIn followers
8,988
Office locations
1

Celltrion Healthcare Canada Limited company summary

Celltrion Healthcare Canada Limited is a company in the Pharmaceutical Manufacturing industry, headquartered in Toronto, Ontario. On LinkedIn the company has around 54 employees and 8,988 followers.

What technology does Celltrion Healthcare Canada Limited use?

No technologies detected yet. Warmrank rechecks company websites on a rolling basis.

About Celltrion Healthcare Canada Limited

Since its humble beginnings in October 2001, Celltrion Healthcare has become one of the world’s recognized players in the area of biosimilars, with operations in over 110 countries and more than 30 worldwide partners. Our goal is to provide effective and affordable therapeutics to patients everywhere. Our dream is to develop innovative new drugs and become a global biopharmaceutical leader. Now, with the opening of operations in Canada, this dream has become a reality for all Canadians who are in need. In January 2021, Celltrion Healthcare received Health Canada marketing authorization for world's first subcutaneous formulation of infliximab, RemsimaTM SC, for the treatment of people with rheumatoid arthritis. Rheumatoid arthritis is the most common chronic inflammatory joint disease, affecting approximately 374,000 Canadians over the age of 16. In December 2021, Celltrion Healthcare Canada received Health Canada marketing authorization for Yuflyma®, a high-concentration (100 mg/mL), low-volume, citrate-free, and latex-free biosimilar to Humira® (adalimumab). Yuflyma® is approved in ten indications for the treatment of multiple chronic inflammatory diseases, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, adult ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, adult uveitis, and pediatric uveitis. We are proud to expand our biosimilar portfolio in Canada, with Remsima™ SC in 2021, and now with Yuflyma®, bringing innovative therapies to help patients on their treatment journey. We will be a contributor to the overall Celltrion journey to become a leading global biopharmaceutical company. At the same time, we will work tirelessly to bring effective therapies to Canadians from coast to coast.

Where is Celltrion Healthcare Canada Limited located?

Celltrion Healthcare Canada Limited lists 1 location.

Toronto, Ontario M5H 3T9, CAHQ
121 King St W

Compare companies similar to Celltrion Healthcare Canada Limited

More companies in Pharmaceutical Manufacturing.

CompanyIndustryEmployeesFoundedHeadquarters
Celltrion Healthcare Canada Limited
celltrionhealthcare.ca
Pharmaceutical Manufacturing54-Toronto, Ontario
Pharmaceutical Manufacturing108,102-New York, New York
Sanofi
sanofi.com
Pharmaceutical Manufacturing93,352-Paris, France, FR
GSK
gsk.com
Pharmaceutical Manufacturing92,179-London, England
Novartis España
novartis.com
Pharmaceutical Manufacturing85,373-Basel, Baselstadt
AstraZeneca
astrazeneca.com
Pharmaceutical Manufacturing80,667-Cambridge, Cambridgeshire, GB
Pharmaceutical Manufacturing57,202-Indianapolis, Indiana
Merck
merck.us
Pharmaceutical Manufacturing44,794-Rahway, New Jersey
SUN PHARMA
sunpharma.com
Pharmaceutical Manufacturing47,7641983Mumbai, Maharastra
Boehringer Ingelheim
boehringer-ingelheim.com
Pharmaceutical Manufacturing47,150-Ingelheim am Rhein, Rhineland-Palatinate
Cipla
cipla.com
Pharmaceutical Manufacturing51,911-Mumbai, Maharashtra

Frequently asked questions about Celltrion Healthcare Canada Limited

What does Celltrion Healthcare Canada Limited do?

Since its humble beginnings in October 2001, Celltrion Healthcare has become one of the world’s recognized players in the area of biosimilars, with operations in over 110 countries and more than 30 worldwide partners. Our goal is to provide effective and affordable therapeutics to patients everywhere. Our dream is to develop innovative new drugs and become a global biopharmaceutical leader. Now, with the opening of operations in Canada, this dream has become a reality for all Canadians who are in need. In January 2021, Celltrion Healthcare received Health Canada marketing authorization for world's first subcutaneous formulation of infliximab, RemsimaTM SC, for the treatment of people with rheumatoid arthritis. Rheumatoid arthritis is the most common chronic inflammatory joint disease, affecting approximately 374,000 Canadians over the age of 16. In December 2021, Celltrion Healthcare Canada received Health Canada marketing authorization for Yuflyma®, a high-concentration (100 mg/mL), low-volume, citrate-free, and latex-free biosimilar to Humira® (adalimumab). Yuflyma® is approved in ten indications for the treatment of multiple chronic inflammatory diseases, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, adult ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, adult uveitis, and pediatric uveitis. We are proud to expand our biosimilar portfolio in Canada, with Remsima™ SC in 2021, and now with Yuflyma®, bringing innovative therapies to help patients on their treatment journey. We will be a contributor to the overall Celltrion journey to become a leading global biopharmaceutical company. At the same time, we will work tirelessly to bring effective therapies to Canadians from coast to coast.

How many employees does Celltrion Healthcare Canada Limited have?

Celltrion Healthcare Canada Limited has around 54 employees on LinkedIn.

Where is Celltrion Healthcare Canada Limited headquartered?

Celltrion Healthcare Canada Limited is headquartered in Toronto, Ontario.

Build a lead list from companies like Celltrion Healthcare Canada Limited

Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.